The science.

DiMarco AV, Ravichandran M, Lau J, Lima A, Lin E, Weng J, Gerosa L, Saenz-Lopez Larrocha P, Hunsaker T, Xiao Y, Miś M, Havnar C, Chen W, Barck KH, Totpal K, Foreman O, Merchant M, Sodir N, Maddalo D. RIT1M90I is a driver of lung adenocarcinoma tumori

DiMarco AV, Ravichandran M, Lau J, Lima A, Lin E, Weng J, Gerosa L, Saenz-Lopez Larrocha P, Hunsaker T, Xiao Y, Miś M, Havnar C, Chen W, Barck KH, Totpal K, Foreman O, Merchant M, Sodir N, Maddalo D. RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy. Preprint (2024)

Garcia NMG, Becerra JN, McKinney BJ, DiMarco AV, Wu F, Fitzgibbon M, Alvarez JV. APOBEC3 activity promotes the survival and evolution of drug-tolerant persister cells during acquired resistance to EGFR inhibitors in lung cancer. bioRxiv (2023)

Garcia NMG, Becerra JN, McKinney BJ, DiMarco AV, Wu F, Fitzgibbon M, Alvarez JV. APOBEC3 activity promotes the survival and evolution of drug-tolerant persister cells during acquired resistance to EGFR inhibitors in lung cancer. bioRxiv (2023)

DiMarco AV and Maddalo D, In Vivo Modeling of Tumor Heterogeneity for Immuno-Oncology Studies: Failures, Improvements, and Hopes. Current Protocols (2022)

DiMarco AV and Maddalo D, In Vivo Modeling of Tumor Heterogeneity for Immuno-Oncology Studies: Failures, Improvements, and Hopes. Current Protocols (2022)

DiMarco AV, Garcia NMG, Alvarez, JV (2022). Therapy-Induced Dormancy and Residual Disease. Chapter in: Leong, S.P., Nathanson, S.D., Zager, J.S. (eds) Cancer Metastasis Through the Lymphovascular System. Springer, Cham

DiMarco AV, Garcia NMG, Alvarez, JV (2022). Therapy-Induced Dormancy and Residual Disease. Chapter in: Leong, S.P., Nathanson, S.D., Zager, J.S. (eds) Cancer Metastasis Through the Lymphovascular System. Springer, Cham

DiMarco AV, Qin X, McKinney BJ, Garcia NMG, Van Alsten SC, Mendes EA, Force J, Hanks BA, Troester MA, Owzar K, Xie J, Alvarez JV. APOBEC mutagenesis inhibits breast cancer growth through induction of T cell–mediated antitumor immune responses. Cancer

DiMarco AV, Qin X, McKinney BJ, Garcia NMG, Van Alsten SC, Mendes EA, Force J, Hanks BA, Troester MA, Owzar K, Xie J, Alvarez JV. APOBEC mutagenesis inhibits breast cancer growth through induction of T cell–mediated antitumor immune responses. Cancer Immunol Res (2022)

Walens A, DiMarco AV, Lupo R, Kroger BR, Damrauer JS, Alvarez JV. CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors. eLife (2019)

Walens A, DiMarco AV, Lupo R, Kroger BR, Damrauer JS, Alvarez JV. CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors. eLife (2019)

Ball JP, Springer MJ, Ni Y, Finger-Baker I, Martinez J, Hahn J, Suber JF, DiMarco AV, Talton JD, Cobb RR. Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder. PLOS One (2017)

Ball JP, Springer MJ, Ni Y, Finger-Baker I, Martinez J, Hahn J, Suber JF, DiMarco AV, Talton JD, Cobb RR. Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder. PLOS One (2017)

Springer MJ, Ni Y, Finger-Baker I, Ball JP, Hahn J, DiMarco AV, Kobs D, Horne B, Talton JD, Cobb RR. Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation. Vaccine (2016)

Springer MJ, Ni Y, Finger-Baker I, Ball JP, Hahn J, DiMarco AV, Kobs D, Horne B, Talton JD, Cobb RR. Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation. Vaccine (2016)